Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model

Shruti M. Phadke, Kazi Islam, Berthony Deslouches, Sunil A. Kapoor, Donna Beer Stolz, Simon C. Watkins, Ronald C. Montelaro, Joseph M. Pilewski, Timothy A. Mietzner

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Lentivirus lytic peptides (LLPs) are derived from HIV-1 and have antibacterial properties. LLP derivatives (eLLPs) were engineered for greater potency against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Minimum bactericidal concentration (MBC) was determined in low and physiologic salt concentrations. MBC was decreased against SA and equivalent against PA in physiologic salt when compared to the parent compound LLP1. In a novel cystic fibrosis (CF) airway cell model, one derivative, WLSA5, reduced the number of adherent PA and only moderately affected CF cell viability. Overall, eLLPs are selectively toxic to bacteria and may be useful against CF airway infections.

Original languageEnglish (US)
Pages (from-to)1099-1107
Number of pages9
Issue number8
StatePublished - Aug 2003
Externally publishedYes


  • Airway epithelial cells
  • Antimicrobial peptide
  • Cystic fibrosis
  • Selective toxicity

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Endocrinology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model'. Together they form a unique fingerprint.

Cite this